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Abstract: Smoking cessation is the only available intervention proven to halt progression of 
chronic obstructive pulmonary disease (COPD). The authors discuss the current existing treat-
ment modalities and the role of a newly approved agent, varenicline, in promotion of smoking 
cessation. Varenicline is a novel agent that is a centrally acting partial nicotinic acetylcholine 
receptor agonist. It has both agonistic and antagonistic properties that together are believed to 
account for reduction of craving and withdrawal as well as blocking the rewarding effects of 
smoking. Its targeted mechanism of action, better efﬁ  cacy and tolerability makes varenicline a 
useful therapeutic option for smoking cessation. In this article, we discuss presently available 
options for smoking cessation and review the literature on efﬁ  cacy of varenicline.
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Introduction
There is signiﬁ  cant evidence to suggest that cigarette smoking is the most important 
factor in the development and progression of COPD (Stang et al 2000). It is esti-
mated that 15% of smokers worldwide will develop clinically symptomatic COPD. 
At the present time, a combination of pharmacological and non-pharmacological 
approaches seems to be effective in an attempt to control the symptoms. Βeta agonists 
and anticholinergics decrease air-trapping and improve exercise capacity by decreas-
ing airway smooth muscle tone and improving expiratory ﬂ  ow. But none of these 
agents have been shown to be disease-modifying therapy. Long-term oxygen therapy 
(LTOT) has been shown to improve survival (NOTT 1980), especially in patients 
with partial pressure of arterial oxygen (PaO2)  60 mmHg (Tarpu and Celli 1995). 
Patients undergoing comprehensive pulmonary rehabilitation program have shown to 
have decreased dyspnea, increased exercise capacity, improved quality of life, fewer 
exacerbations, lesser hospital stays and improved cardiovascular status (Lacasse 1996; 
Grifﬁ  ths et al 2000; Guell et al 2000).
Lung volume reduction surgery (LVRS) seem to beneﬁ  t patients with upper lobe 
disease and low exercise capacity (1-year mortality rate was 7%). Lung transplanta-
tion improves quality of life and functional status in selected patients with advanced 
COPD (FEV1 35% predicted, PaO2 of 55–60 mmHg and partial pressure of arterial 
carbon dioxide (PaCO2)  50 mmHg) (Hosenpud et al 2001). Studies are underway to 
evaluate survival outcomes in patients with COPD following lung transplantation.
Smoking cessation and its treatment modalities
Smoking cessation remains the single most important intervention in preventing disease 
onset and in preserving lung function (Meinke et al 2007). Several pharmacological 
interventions now exist to aid smokers in cessation. Drug therapy has been increas-
ingly relied upon to assist in smoking cessation.
The most common of these has been nicotine replacement therapy (NRT) which 
includes transdermal patch, gum, inhaler, nasal spray, and lozenges. A meta-analysis 
including 70 trials assessing NRT versus placebo at 1 year showed odds ratio (OR) of International Journal of COPD 2008:3(2) 240
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1.71 favoring NRT (95% conﬁ  dence interval [CI]: 1.55–1.88, 
p   0.0001). The same meta-analysis evaluated 59 trials 
providing sufﬁ  cient data to determine short-term effects of 
NRT on smoking cessation at 3 months. The pooled OR of 
these 59 trials was 1.98 (95% CI, 1.77–2.21, p   0.0001) 
(Wu et al 2006).
A cochrane database systemic review (Silagy et al 2004) 
showed that out of 103 trials comparing NRT and a placebo 
or non-NRT control group, OR for abstinence with NRT com-
pared with control was 1.77 (95% CI 1.66–1.88). The ORs 
for the different forms of NRT were 1.66 (95% CI 1.52–1.81) 
for gum, 1.81 (95% CI 1.63–2.02) for patches, 2.35 (95% 
CI 1.63–3.38) for nasal spray, 2.14 (95% CI 1.44–3.18) for 
inhaled nicotine, and 2.05 (95% CI 1.62–2.59) for nicotine 
sublingual tablet/lozenge. In highly addicted smokers there 
was a signiﬁ  cant beneﬁ  t of 4 mg gum compared with 2 mg 
gum (OR 2.20, 95% CI 1.85–3.25). There was weak evidence 
that combinations of forms of NRT are more effective. The 
most signiﬁ  cant adverse events with NRT were mouth or 
throat irritation, skin irritation, nausea/vomiting, coughing, 
hiccoughs, dyspepsia, watering of eyes, headaches, palpita-
tions, and insomnia (Wu et al 2006).
Bupropion is a weak dopamine and nor-epinephrine 
reuptake inhibitor. Like NRT products, bupropion has been 
endorsed by the US Clinical Practice Guidelines (Fiore et al 
2000) as a ﬁ  rst-line therapy. Bupropion has been shown 
to approximately double rates of cessation compared with 
placebo, and the medication is equally effective for men and 
women (Scharf and Shiffman 2004). The pooled OR from 12 
trials evaluating the effect of bupropion on smoking cessa-
tion relative to adequate controls at 1 year was 1.56 (95% CI 
1.10–2.21, p = 0.01). The OR for sustained abstinence was 
1.52 (11 trials, 95% CI 1.04–2.23, p   0.0001). When the 
effect of bupropion on placebo at 3 months were evaluated, 
the OR was 2.13 (11 trials, 95% CI 1.72–2.64, p   0.0001) 
and for the sustained abstinence measures, the OR was 2.18 
(8 trials, 95% CI 1.67–2.86, p   0.0001). The following 
were the adverse events observed in bupropion trials: dry 
mouth, insomnia, gastrointestinal upset, and constipation 
(Wu 2006). Its use is relatively contraindicated in smokers 
with a history of seizures, head trauma, heavy alcohol abuse, 
or anorexia.
Besides NRT products and bupropion, two medica-
tions (nortriptyline and clonidine) are endorsed by the US 
Clinical Practice Guidelines (Fiore et al 2000) as second-line 
therapies. Nortriptyline in combination with transdermal 
nicotine was also shown to enhance the cessation rates above 
levels seen with transdermal nicotine alone (Prochazka et al 
2004). The tricyclic antidepressant doxepin has also been 
shown in a small human study to improve cessation rates 
(Edwards et al 1989). One study of heavy smokers who had 
failed in previous quit attempts found that those treated with 
clonidine, an alpha-2-noradrenergic agonist, had twice the 
rate of abstinence as those treated with placebo at the end 
of the 4-week treatment (Glassman et al 1988). This effect 
continued through the 6-month follow up. These results 
suggest that clonidine may be efﬁ  cacious in the treatment 
of tobacco dependence, but the conditions under which it is 
most appropriately used are not well deﬁ  ned.
Behavioral modiﬁ  cations for smoking cessation include 
intense hypnotherapy and acupuncture. A prospective pilot 
trial of intensive hypnotherapy was performed involving 
20 patients with multiple individual sessions (8 visits) 
over approximately 2 months. Self-reported abstinence 
was conﬁ  rmed by a carbon monoxide concentration in 
expired air of 8 ppm or less. The rates of point prevalence 
smoking cessation, as conﬁ  rmed by carbon monoxide 
measurements for the intensive hypnotherapy group, was 
40% at the end of treatment; 60% at 12 weeks, and 40% 
at 26 weeks (p   0.05) (Elkins et al 2006). There is no 
clear evidence that acupuncture, acupressure, laser therapy 
or electrostimulation are effective for smoking cessation 
(White et al 2002).
The most recent guidelines on tobacco use and depen-
dence from the United States Public Health Service (USPHS) 
places a much greater emphasis on the role of assessment 
of readiness to change and motivating behavior change in 
smoking cessation (USPHS 2000). As behavioral approaches 
to smoking cessation became more reﬁ  ned, delivery systems 
for cessation also improved. One of the most important 
developments has been evolution of telephone counseling for 
smoking cessation. Research trials have shown increased rate 
of smoking cessation at one year for callers to the California 
Smokers Helpline who received 7 telephone counseling ses-
sions when compared to non-counseled smokers (9.1 vs 6.9% 
cessation) (Zhu et al 2002). The USPHS Clinical Practical 
Guideline recommends multiple types of clinicians provid-
ing counseling over at least 4 sessions with a total contact 
time of at least 30 minutes for intensive interventions. Both 
counseling and pharmacotherapy are accepted means of 
enhancing smoking cessation among smokers. There are also 
several cessation aides like self-help and print materials for 
tobacco cessation that have been available (Lancaster and 
Stead 2002). Further reﬁ  nement of such materials, allowed 
for culturally appropriate cessation aids should be delivered 
to various groups of tobacco users.International Journal of COPD 2008:3(2) 241
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Nicotine receptor partial agonists may help smokers to 
quit by a combination of maintaining moderate levels of 
dopamine to counteract withdrawal symptoms (acting as 
an agonist) and reducing smoking satisfaction (acting as an 
antagonist). Cytisine is an agonist of nicotinic receptors; in 
particular, it binds strongly with α4β2 nicotinic receptors. 
Cytisine was developed as a treatment for tobacco depen-
dence in Bulgaria in 1960s, and is still commercially available 
in central and eastern Europe. In the 1960s an early smoking 
cessation study with cytisine failed to exhibit robust efﬁ  cacy, 
possibly as a result of poor absorption (Barlow and McLead 
1969), and limited brain penetration (Reavill et al 1990). The 
Tabex trial detected a beneﬁ  t of cytisine compared with pla-
cebo at 2-year follow up (OR 1.77, 95% CI 1.30–2.40). The 
OR for this trial at 6 months was 2.30 (95% CI 1.75–3.04) 
(Scharfenberg et al 1971). More recently, efforts to combine 
nicotine replacement therapy with the nicotinic antagonist 
mecamylamine were more successful (Rose et al 1994). 
These latter results of combining an agonist and antagonist-
essentially creating a partial agonist-suggested that an agent 
with an optimal partial agonist proﬁ  le and physicochemical 
properties could provide improved relief to patients during 
smoking cessation attempts.
Furthermore, a recent meta-analysis looking at efﬁ  cacy 
of cytisine in smoking cessation showed that the pooled 
odds ratio after 3–8 weeks in 3 placebo-controlled trials was 
1.93 (95% CI 1.21–3.06). For the two placebo-controlled 
double-blind trials with a longer follow-up, the pooled 
odds ratio after 3–6 months was 1.83 (95% CI 1.12–2.99) 
(Etter 2006).
Varenicline was developed as a nicotine receptor 
partial agonist from cytisine, which is also a naturally 
occurring alkaloid compound (Cahill et al 2007). In the 
studies described below, varenicline was identiﬁ  ed to be 
more effective than placebo, bupropion, and NRT. Despite 
several efforts in creating awareness of deleterious effect 
of smoking, it is still a major issue around the world. Even 
though there are several interventions available for smoking 
cessation, varenicline is the ﬁ  rst drug designed to interact 
with a key brain receptor involved in nicotine addiction. 
This article covers the history of varenicline development 
and its pharmacodynamics, and reviews the current data 
on its efﬁ  cacy.
Neurobiology of nicotine addiction
Nicotine, the primary psychoactive component of tobacco 
smoke, produces diverse neurophysiological, motivational, 
and behavioral effects through several brain regions and 
neurochemical pathways. Recent research in the ﬁ  elds of 
behavioral pharmacology, genetics, and electrophysiology is 
providing an increasingly integrated picture of how the brain 
processes the motivational effects of nicotine.
Nicotine alters the function of several CNS neurotrans-
mitters, including dopamine (DA), noradrenaline (NA), 5-
hydroxytryptamine (5-HT), glutamate, gamma-aminobutryic 
acid (GABA), and endogenous opioid peptides (EOPs). 
It primarily affects the nervous system through the action 
of nicotinic acetylcholine receptors (nAChRs), ionotropic 
receptors that are widely distributed through the brain 
(Figure 1). The effects of α4-receptor activation have been 
shown to be important in dependence, including reinforce-
ment, tolerance and sensitization (Tapper et al 2004). The 
dysphoric symptoms of nicotine withdrawal start to occur 
when the regular smoker is deprived of nicotine for at least 
4–6 hours and when more nAChRs become resensitized but 
unstimulated by nicotine.
Many effective pharmacotherapies as mentioned earlier 
such as NRT, bupropion and nortriptyline appear to affect 
neurobiological mechanisms of nicotine dependence. They 
decrease nicotine withdrawal by inhibiting reuptake of dopa-
mine and norepinephrine in the central nervous system, but 
without the need for a direct agonist effect (Roddy 2004). 
Compounds that act as α4β2 nAChR partial agonists and 
simultaneously block the action of nicotine (Cohen et al 
2003; Coe et al 2005) offer a particularly promising new 
approach to helping smokers quit. This article reviews one 
such compound: varenicline.
History of  varenicline development
Varenicline tartrate (Chantix®; Pﬁ  zer), an α4β2 nicotinic 
receptor partial agonist, was approved by the US FDA as an 
aid to smoking cessation treatment on May 11, 2006 (Niaura 
et al 2006). It was hypothesized that a partial agonist of α4β2 
nAChRs would lead to a moderate and sustained increase 
of mesolimbic dopamine levels. This might counteract the 
low dopamine levels that result from a lack of nicotine dur-
ing attempts to quit smoking, which seem to be important 
in craving and withdrawal, and could therefore be crucial in 
leading to relapse to smoking. By also competitively bind-
ing to α4β2 nAChRs, a partial agonist might shield a smoker 
from nicotine-induced increases in dopamine levels thereby 
preventing any events of relapse. Thus it was thought that 
a partial agonist of α4β2 nAChR might aid in smoking ces-
sation (Figure 2).
Cytisine, which is an alkaloid extracted from the seeds 
of Cystisus laburnum, is a partial agonist of the nChR International Journal of COPD 2008:3(2) 242
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Figure 1 Simpliﬁ  ed structure of α7 and α4β2 nicotinic receptor located on surface of a dopamine cell body.
and antagonizes the receptor response to its endogenous 
neurotransmitter, acetylcholine (Papke and Heinemann 
1994). Varenicline was discovered through the synthesis of a 
series of compounds inspired by this natural product cytisine 
(Cohen et al 2003). Varenicline was found to be a selective 
partial agonist at the α4β2 nAChR, displaying 30%–60% of 
the in vivo efﬁ  cacy of nicotine, and also blocked the in vivo 
response to nicotine (Coe et al 2005).International Journal of COPD 2008:3(2) 243
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Pharmacokinetics of  varenicline
Varenicline (7,8,9,10-tetrahydro-6,10-methano-6H-
pyrazino[2,3-h][3]benzazepine) is a partial agonist selective 
for the α4β2 nicotinic acetylcholine receptor subtype (Figure 3). 
This tartrate salt is highly soluble in water, with a molecular 
weight of 361.35 Da (Zieler-Brown and Kyle 2007).
Maximal plasma concentrations of varenicline are 
reached within 3–4 hours and steady-state concentration 
occurs within 4 days. Over the recommended dosing range, 
varenicline exhibits linear pharmacokinetics after single 
or repeated doses. In a mass balance study, absorption of 
varenicline was virtually complete after oral administration 
and systemic availability was high. Varenicline has a half-
life of 24 hours and its bio-availability is not affected by 
food or time of administration. Varenicline exhibits linear 
pharmacokinetics and low plasma protein binding (20%), 
regardless of a patient’s age and renal function (Faessel et al 
2006a). Varenicline appears to be effective for adults, regard-
less of age, race, gender, or smoking status. No safety data 
have been established for subjects under 18 years of age. This 
is a pregnancy class C drug (uncertain safety).
Varenicline is usually well tolerated after single doses up to 
3.0 mg in smokers. At doses of 10.0 mg under fasting conditions, 
nausea and vomiting may occur. The underlying mechanisms 
responsible for the dose-related toleration and side effects are 
unclear at this time but are consistent with the pharmacologic 
actions of other nicotinic agents (Srivastava et al 1991; Perkins 
et al 1994). The overall mean tmax is about 2.9 hours in smokers 
and 2.6 hours in nonsmokers. Plasma varenicline concentra-
tions decline within 10.1 hours to 25.6 hours in smokers and 
8.1–30.2 hours in nonsmokers. Dose-proportional increases 
are observed in systemic exposure, based on Cmax and AUC0 
values, after single and repeat dosing between the 1-mg and
2-mg doses of varenicline (Faessel et al 2006b). Smoking 
restriction does not affect the pharmacokinetics of varenicline 
in smokers. The pharmacokinetic disposition of varenicline in 
elderly smokers with normal renal function is similar to that in 
younger, healthy persons (Burstein et al 2006).
Varenicline’s method of excretion and its metabolites 
were analyzed in both animal and human studies (Obach et al 
2006). This study showed that the majority of drug-related 
material is excreted in the urine, with a substantial portion of 
this being represented by the parent drug rather than metabo-
lites. In humans, greater than 90% of the recovered compound 
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was unchanged varenicline, indicating that renal secretion 
of varenicline is a major route of drug clearance. In other 
work using in vitro approaches, it has been demonstrated that 
although varenicline can readily penetrate biological mem-
branes by passive diffusion, it is also a substrate for human 
organic cation transporter 2, a renal transport protein involved 
in active secretion of cationic drugs (Rollema et al 2006).
Varenicline has few metabolites. There is no readily 
observable difference in serum levels of these metabolites 
between smokers and nonsmokers. Most of orally ingested 
varenicline is excreted unchanged in the urine. However, 
there are two inactive metabolites that are observed in urine: 
2-hydroxyvarenicline and varenicline N-carbamoylglucuro-
nide (Obach et al 2006). These were primarily derived from 
reactions occurring at the alicyclic nitrogen.
Review of current data
on varenicline
Several studies have shown how effective and useful vareni-
cline is in smoking cessation. There are few landmark ran-
domized trials on the efﬁ  cacy of the nicotinic acetylcholine 
receptor partial agonist varenicline for achieving smoking 
cessation.
One trial compared the safety and efﬁ  cacy of varenicline 
for smoking cessation with sustained-release bupoprion 
and placebo in a multicenter randomized, double-blind, 
placebo-controlled trial (Gonzales et al 2006). Participants 
were 1025 generally healthy smokers (10 cigarettes per day) 
with fewer than 3 months of smoking abstinence in the past 
year, 54% male and mean age of 42.4 years. Participants 
were randomly assigned in a 1:1:1 ratio to receive brief 
counseling and varenicline titrated to 1 mg twice per day 
(n = 352), bupropion SR titrated to 150 mg twice per day 
(n = 329), or placebo (n = 344) orally for 12 weeks, with 
40 weeks of follow-up. Study completion rates were 60%, 
56%, and 54% for varenicline, bupropion SR, and placebo, 
respectively. At baseline, patients smoked an average of 21 
cigarettes per day and had smoked for an average of 24 years. 
Continuous abstinence rates from weeks 9 to 12 – the primary 
endpoint – were 44.0% for varenicline vs 17.7% for placebo 
(OR 3.85, 95% CI 2.70–5.50, p   0.001) and vs 29.5% for 
bupropion SR (OR 1.93, 95% CI 1.40–2.68, p   0.001). By 
this measure, varenicline was superior to bupropion SR and 
placebo. The continuous abstinence rate for weeks 9–24 
was superior for varenicline (29.5%) vs placebo (10.5%) 
(OR 3.68, 95% CI 2.42–5.60, p   0.001) and vs bupropion 
SR (20.7%) (OR 1.63, 95% CI 1.14–2.33, p = 0.007). For 
weeks 9 through 52, the continuous absitence rates were 
21.9% for varenicline vs 8.4% for placebo (OR: 3.09, 95% 
CI: 1.95–4.91, p   0.001) and vs 16.1% for bupropion SR 
(OR: 1.46, 95% CI: 0.99–2.17, p = 0.057). Compared with 
placebo, bupropion SR and varenicline both reduced some 
symptoms of withdrawal, cigarette craving, and smoking 
reinforcement. The varenicline and placebo groups had the 
same rates of stopping treatment because of side effects; the 
rate for bupropion SR was higher.
This study also measured the effects of varenicline and 
bupropion SR in comparison with placebo on craving and 
withdrawal symptoms by The Brief Questionnaire of Smok-
ing Urges (QSU-brief) and Minnesota Nicotine Withdrawal 
Scale (MNWS). As assessed by subscales of MNWS, vareni-
cline and bupropion SR signiﬁ  cantly reduced urge to smoke 
and negative affect compared with placebo (p   0.001). The 
effect size of the difference from placebo for varenicline was 
about twice that of bupropion SR on urge to smoke. Results 
from QSU-brief demonstrated that, compared with placebo, 
the total craving score was signiﬁ  cantly less for both vareni-
cline (p   0.001) and bupropion SR (p = 0.001).
An important feature of this study design was the inclu-
sion of bupropion, the only previously approved smoking 
cessation medication not containing nicotine, as an active 
compare. To prevent a negative bias against bupropion, 
individuals who had any prior exposure to bupropion were 
excluded. However, this study does not address the effects 
of varenicline on smokers with a history of bupropion use. 
Since some smokers may have taken bupropion for smoking 
cessation or treatment of depression, there may be limitations 
when interpreting these results for a broader population. This 
study concluded that varenicline was signiﬁ  cantly more efﬁ  -
cacious than placebo for smoking cessation at all time points 
and signiﬁ  cantly more efﬁ  cacious than bupropion SR at the 
end of 12 weeks of drug treatment and at 24 weeks.
The above results were conﬁ  rmed by another study 
that determined the efﬁ  cacy and safety of varenicline 
for smoking cessation compared with placebo or sus-
tained-release bupropion in a randomized, double-blind, 
placebo-controlled trial at 14 research centers. This study 
enrolled 1027 healthy adult volunteers, 58% male and 
mean age of 43.3 years, with a 12-week treatment period 
and follow-up of smoking status to week 52 (Jorenby et al 
2006). Varenicline titrated to 1 mg twice daily (n = 344) or 
bupropion SR titrated to 150 mg twice daily (n = 342) or 
placebo (n = 341) for 12 weeks, plus weekly brief smoking 
cessation counseling. During the last 4 weeks of treatment 
(weeks 9–12), 43.9% of participants in the varenicline group 
were continuously abstinent from smoking compared with International Journal of COPD 2008:3(2) 245
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17.6% in the placebo group (OR 3.85, 95% CI 2.69–5.50, 
p   0.001) and 29.8% in the bupropion SR group (OR 
1.90, 95% CI 1.38–2.62, p = 0.001). For weeks 9 through 
24, 29.7% of participants in the varenicline group were 
continuously abstinent compared with 13.2% in the pla-
cebo group (OR 2.83, 95% CI 1.91–4.19, p   0.001) and 
20.2% in the bupropion group (OR 1.69, 95% CI 1.19–2.42, 
p = 0.003). For weeks 9 through 52, 23% of participants 
in the varenicline group were continuously abstinent com-
pared with 10.3% in the placebo group (OR 2.66, 95% CI 
1.72–4.11, p   0.001) and 14.6% in the bupropion SR group 
(OR 1.77, 95% CI 1.19–2.63, p = 0.004). Treatment was 
discontinued due to adverse events by 10.5% of participants 
in the varenicline group, 12.6% in the bupropion SR group, 
and 7.3% in the placebo group. The most common adverse 
event with varenicline was nausea, which occurred in 101 
participants (29.4%).
Also in this study, in comparison with participants in the 
placebo group for the average over weeks 1 through 7, those 
in the varenicline group reported signiﬁ  cantly less of an urge 
to smoke (p   0.001) and had less negative affect (p = 0.001) 
as assessed by the MNWS. The results of the QSU-brief 
paralleled those of the MNWS with regard to craving, with 
both varenicline and bupropion SR reducing total craving 
compared with placebo (p   0.001 for both).
In another multicenter, double-blind, placebo-controlled, 
dose-ranging study, the effects of 4 varenicline dose regi-
mens (0.5 mg twice daily, 1 mg twice daily, titrated, and 
nontitrated) for promoting smoking cessation were evaluated 
(Oncken et al 2006). The study involved a longer treatment 
phase (12 weeks) followed by a 40-week assessment after 
discontinuation of the regimen. This study included 647 
healthy volunteer smokers, aged 18–65, smoking at least 
10 cigarettes per day and 49.5% of them were male. The 
primary efﬁ  cacy endpoints were the 4-week continuous quit 
rates for weeks 4 through 7 and 9 through 12 for the pooled 
(titrated and nontitrated) dose groups and abstinence was 
assessed by subject self-report conﬁ  rmed by expired carbon 
monoxide. Weeks 9 through 12 continuous quit rates were 
greater in the 1.0-mg group (49.4%) and the 0.5-mg group 
(44.0%) vs placebo (11.6%; p   0.001 vs both doses). Weeks 
9 through 52 abstinence rates were greater in the 1.0-mg 
group (22.4%; p   0.001) and the 0.5-mg group (18.5%; 
p   0.001) vs placebo (3.9%). Varenicline was generally 
well tolerated, with nausea occurring in 16% to 42% of 
varenicline-treated subjects. Reports of nausea were lower 
for the titrated vs nontitrated dosing and infrequently led to 
medication discontinuation.
A limitation of the study is the optional follow-up study 
design. Subjects who abstained from smoking during weeks 
9 through 12 and who did not enter the follow-up phase 
were counted as smokers, which may have lowered the true 
long-term efﬁ  cacy rates (particularly in the 0.5-mg twice-
daily group). However, even if the subjects who did not 
enter the follow-up truly remained abstinent from smoking 
at 1 year, this would have underestimated the true long-term 
quit rate by only 4% in the 0.5-mg twice-daily group, 1.5% 
in the 1.0-mg twice-daily group, and 2.3% in the placebo 
group. Since approximately 90% of subjects who completed 
treatment continued in the follow-up phase, the analyses 
conducted likely represents a reasonable estimation of long-
term quit rates. This study concluded that varenicline tartrate 
(0.5-mg and 1.0-mg doses taken twice daily for 12 weeks) 
signiﬁ  cantly improved short- and long-term abstinence rates 
compared with placebo. In this study, too, varenicline signiﬁ  -
cantly reduced the urge to smoke and withdrawal compared 
with placebo as measured by MNWS score.
In another randomized, multicenter, double-blind, pla-
cebo- and bupropion-controlled phase 2 (dose-ranging) 
study, 638 healthy smokers (18–65 years old, 10 cigarettes 
per day, and 48% male) were randomized to varenicline 
tartrate, 0.3 mg once daily (n = 128), 1.0 mg once daily 
(n = 128), or 1.0 mg twice daily (n = 127), for 6 weeks plus 
placebo for 1 week; to 150 mg sustained-release bupropion 
hydrochloride twice daily (n = 128) for 7 weeks; or to 
placebo (n = 127) for 7 weeks. Forty-four per cent of the 
subjects had previously used transdermal nicotine replace-
ment therapy (Nides et al 2006). During the treatment phase, 
the continuous quit rates for any 4 weeks were signiﬁ  cantly 
higher for varenicline tartrate, 1.0 mg twice daily (48.0%, 
OR 4.71, 95% CI 2.60–8.53, p   0.001) and 1.0 mg once 
daily (37.3%, OR 2.97, 95% CI 1.63–5.40, p   0.001), than 
for placebo (17.1%). The bupropion quit rate was 33.3% (OR 
2.53, 95% CI 1.38–4.63, p = 0.002) vs placebo. The carbon 
monoxide-conﬁ  rmed continuous quit rates from week 4–52 
were signiﬁ  cantly higher in the varenicline tartrate, 1.0-mg 
twice-daily, group compared with the placebo group (14.4% 
vs 4.9%, p = 0.002). The bupropion rate was 6.3% (p = 0.60) 
vs placebo. Discontinuation owing to treatment-emergent 
adverse events was 15.9% for bupropion, 11.2% to 14.3% for 
varenicline, and 9.8% for placebo. This study demonstrated 
superior efﬁ  cacy of varenicline for short- and long-term (up 
to 1 year) smoking cessation compared with placebo.
When compared with placebo, varenicline 1 mg twice 
daily signiﬁ  cantly reduced craving and several aspects of 
smoking reinforcement. Although subjects were still smoking International Journal of COPD 2008:3(2) 246
Mohanasundaram et al
during the ﬁ  rst week of treatment, only 1 mg twice daily of 
varenicline was effective in reducing the reinforcing effects 
of smoking as measured by the smoking satisfaction scale.
A limitation of this study was the inclusion of subjects 
who had previously failed bupropion therapy – about 
13%–20% had failed bupropion therapy for smoking ces-
sation before study enrollment. The distribution of these 
patients among treatment groups was not reported. Theoreti-
cally, inclusion of these nonresponders to bupropion therapy 
could lead to a lower abstinence rate in the bupropion group, 
and make varenicline seem more efﬁ  cacious in comparison. 
The above-mentioned four studies could be generalized 
to a cohort of middle-aged healthy male smokers who are 
willing to quit.
One of the landmark trials addressed the issue of prevent-
ing relapse, after quitting (Tonstad et al 2006). Although 
50% of smokers can achieve abstinence for several weeks, 
50%–60% of quitters resumed smoking within 1 year. Out 
of 2416 screened patients, 1928 were assigned to receive 
open-label varenicline for 12 weeks. They then randomly 
assigned those who had been abstinent during the 12th week 
(1210 successful quitters, 49% male, mean age 45 years) to 
receive either varenicline or placebo for 12 weeks of double-
blind treatment. Regardless of smoking status, everyone 
then continued in a nontreatment phase for an additional 
28 weeks, for a total of 52 weeks. The dose of varenicline 
was 1.0 mg twice daily, double the dose of the other two 
trials. The primary endpoint was reported abstinence from 
any nicotine product during the double-blind treatment 
phase, as conﬁ  rmed by negative results on an exhaled carbon 
monoxide test.
A total of 1210 of the 1928 patients (62.8%) were 
abstinent during the 12th week of the open-label treatment 
phase and eligible for randomization. The carbon monox-
ide-conﬁ  rmed continuous abstinence rate was signiﬁ  cantly 
higher for the varenicline group than for the placebo group for 
weeks 13–24 (70.5% vs 49.6%, OR 2.48, 95% CI 1.95–3.16, 
p   0.001) as well as for weeks 13–52 (43.6% vs 36.9%, OR 
1.34, 95% CI 1.06–1.69, p = 0.02). The authors concluded 
that extended use of varenicline helps recent ex-smokers to 
maintain their abstinence and prevent relapse. Varenicline 
is the ﬁ  rst drug aimed at smoking cessation to demonstrate a 
signiﬁ  cant long-term effect. However, a temporary accelera-
tion of the rate of relapse occurred in the varenicline group 
after the withdrawal of medication. This study also proved 
that with 1 year follow up, more than 50% of participants in 
both varenicline and placebo groups returned to smoking. 
Discontinuation of varenicline in participants randomized to 
placebo at week 12 was followed by a mean urge-to-smoke 
value that was small and only modestly higher than that of 
double blinded varenicline participants. The above-men-
tioned clinical trials are summarized in Table 1.
More recently, the safety of long-term varenicline admin-
istration for smoking cessation was assessed (Williams et al 
2007). In this randomized, double-blind, multicenter trial, 
eligible adult smokers (18–75 years) who smoked an average 
of  10 cigarettes/day were randomized to either varenicline 
1 mg twice daily or placebo for 52 weeks. Subjects made 
weekly clinic visits until week 8, and then every 4 weeks until 
week 52, with a follow-up visit at week 53. The target quit 
date was the morning of the week 1 clinic visit. Brief counsel-
ing was provided at each visit, and vital signs, adverse events 
(AEs), and smoking status were documented. A total of 251 
subjects were randomized to varenicline and 126 to placebo. 
Approximately half of the subjects in each arm completed the 
study (53.8% varenicline; 46.8% placebo). AEs were noted 
in 96.4% of treatment arm and 82.5% in the placebo arm. 
Common varenicline-associated AEs were nausea (40.2%), 
abnormal dreams (22.7%), and insomnia (19.1%). AEs lead-
ing to discontinuation of varenicline treatment included nau-
sea (7.6%), insomnia (3.2%), and abnormal dreams (2.4%). 
A single varenicline-related serious AE, bilateral subcapsular 
cataracts, was observed. At week 52, 7-day point prevalence 
abstinence rates were 36.7% (varenicline) and 7.9% (placebo) 
(Table 2). The authors concluded that varenicline 1 mg twice 
daily can be safely administered for up to 1 year. Varenicline 
was also a more effective smoking cessation aid than placebo 
throughout the study, supporting both its short- (12-week) 
and long-term (52-week) efﬁ  cacy.
A systematic review and meta-analysis to evaluate 
effectiveness of smoking cessation therapies was conducted 
(Wu et al 2006). In this study, the authors discussed that 
varenicline was superior to placebo at 1 year (4 randomized 
controlled trials (RCTs), OR 2.96, 95% CI 2.12–4.12, 
p 0.0001) and also at approximately 3 months (OR 3.75, 
95% CI 2.65–5.30). Three RCTs evaluated the effectiveness 
of varenicline versus bupropion at 1 year (OR 1.58, 95% CI 
1.22–2.05) and at approximately 3 months (OR 1.61, 95% 
CI 1.16–2.21). Using indirect comparisons, varenicline was 
superior to NRT when compared to placebo controls (OR 
1.66, 95% CI 1.17–2.36, p = 0.004) or to all controls at 1 year 
(OR 1.73, 95% CI 1.22–2.45, p = 0.001). They concluded 
that NRT, bupropion, and varenicline all provide therapeu-
tic effects in assisting with smoking cessation. Direct and 
indirect comparisons identify a hierarchy of effectiveness 
(Wu et al 2006).International Journal of COPD 2008:3(2) 247
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Table 1 Summary of clinical trials
Reference Design Sample (N) Treatment Abstinence rate
Gonzales (2006) Double-blind, comparative; 12 wks 
treatment, 52 wks post-treatment
352 Varenicline 1 mg twice daily Weeks 9–12
 Varenicline  44%
  Buproprion SR 30%
 Placebo  17% 
Weeks 9–24
 Varenicline  29%
  Buproprion SR 21%
 Placebo  11%
Weeks 9–52
 Varenicline  22%
  Buproprion SR 16%
 Placebo  8%
329 Buproprion SR 150 mg twice 
daily
344 Placebo
Jorenby (2006) Double-blind, comparative; 12 wks 
treatment, 52 wks post-treatment
344 Varenicline 1 mg twice daily Weeks 9–12
 Varenicline  44%
  Buproprion SR 30%
 Placebo  17%
Weeks 9–24
 Varenicline  29%
  Buproprion SR 20%
 Placebo  13%
Weeks 9–52
 Varenicline  23%
  Buproprion SR 14%
 Placebo  10%
342  Buproprion SR 150 mg twice 
daily
341 Placebo
Ocken (2006) Double-blind, phase 2, multicenter, 
placebo controlled. 12 wks treatment, 
40 wks post-treatment
129 Varenicline 0.5 mg nontitrated 
(twice daily for 12 wks)
Weeks 4–7
   Varenicline 0.5 mg twice daily 36.3%
  Varenicline 1 mg twice daily 39.8%
 Placebo  10.9%
Weeks 9–12
  Varenicline 0.5 mg twice daily 44%
  Varenicline 1 mg twice daily 49.4%
 Placebo  11.6%
Weeks 9–52
   Varenicline 0.5 mg twice daily 18.5%
  Varenicline 1 mg twice daily 22.4%
 Placebo  3.9%
130 Varenicline 0.5 mg titrated 
(wk 1 once daily, wks 2–12 
twice daily)
129 Varenicline 1 mg nontitrated 
(twice daily for 12 wks)
130 Varenicline 1 mg titrated 
(0.5 mg once daily for 3 days, 
0.5 mg twice daily for 4 days, 
1 mg twice daily wks 2–12)
129 Placebo twice daily for 12 wks
Nides (2006) Double-blind, phase 2, multicenter, 
placebo controlled. 7 wk treatment 
(6 wk + 1 wk placebo or 7 wks 
buproprion/ placebo), 8–52 wks 
post-treatment
128 Varenicline 0.3 mg once daily Weeks 0–4
  Varenicline 1 mg twice daily 48%
  Varenicline 1 mg once daily 37.3%
  Buproprion SR 33.3%
 Placebo  17.1%
Weeks 4–52
  Varenicline 1 mg twice daily 14.4%
  Varenicline 1 mg once daily 37.3%
 Buproprion  SR  6.3%
 Placebo  4.9%
128 Varenicline 1 mg once daily
127 Varenicline 1 mg twice daily
128 Buproprion SR 150 mg twice 
daily
127 Placebo
Tonstad (2006) Double-blind phase, long-term 
abstinence, open-label, 12 wk 
treatment, 13–52 wks post-treatment
603 Varenicline 1 mg twice daily Weeks 13–24
 Varenicline  70%
 Placebo  50%
Weeks 13–52
 Varenicline  44%
 Placebo  39%
607 Placebo
Abbreviations: wk, week; SR, sustained release.International Journal of COPD 2008:3(2) 248
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The literature reviewed here suggests that varenicline 
shows efﬁ  cacy comparable to that of bupropion SR and 
superior to that placebo. No safety or efﬁ  cacy data have been 
established for varenicline use in combination with other 
smoking cessation medications.
Dosage and administration
Varenicline has FDA approval as monotherapy. Vareni-
cline is supplied orally in 2 strengths: 0.5 mg and 1.0 mg. 
Varenicline treatment should be initiated 1 week prior to a 
quit date. The titration schedule consists of a 1-week lead-in 
phase followed by a dose of 1 mg twice daily. The gradual 
increase in titration is recommended to limit the occurrence 
of nausea. A 12-week course of treatment is recommended, 
with an additional 12 weeks included to ensure long-term 
abstinence. Successive attempts are recommended for those 
who relapse or fail therapy. The titration schedule is as fol-
lows: days 1–3, 0.5 mg daily; days 4–7, 0.5 mg twice daily; 
and, starting on day 8, 1.0 mg twice daily. A maximum 
dosage of 0.5 mg daily is recommended for patients under-
going hemodialysis for end-stage renal disease (Chantix: 
Package insert).
The estimated 12-month employer cost savings (US$) per 
nonsmoking employee were $540.60 for varenicline, $269.80 
for bupropion SR generic, $150.80 for bupropion SR brand, 
and $81.80 for placebo (Jackson et al 2007). Varenicline was 
more cost beneﬁ  cial than placebo, which had quit rates of 
16.9% or less. The quit rate with varenicline would have to be 
 16.9% to lose cost beneﬁ  t over bupropion SR generic. The 
authors, hence, conclude that the economic beneﬁ  t of vareni-
cline is better than that of bupropion, despite the increased 
initial cost of varenicline. The initial month's blister pack is 
estimated to cost $100, while reﬁ  lls of the blister packs are 
to range between $90 and $100. Total cost associated with 
a 12-week course of therapy is estimated to be $300 (Zieler-
Brown and Kyle 2007). This is in comparison with NRTs that 
cost about $4–$15 per day, nicotine inhaler that costs $45 per 
package, and bupropion that costs $2 per day.
Dosage adjustments are required for patients with renal 
insufﬁ  ciency but not in hepatic insufﬁ  ciency (Molander et al 
2001). Drug–drug interactions have been evaluated, with 
no clinically signiﬁ  cant ﬁ  ndings shown with varenicine or 
co-inhibitors of the human organic cation transporter, which 
mediates renal secretion of varenicline. Substrates such as 
warfarin, digoxin, cimetidine, metformin, bupropion, and 
transdermal nicotine do not alter pharmacokinetic parameters 
when coadministered with varenicline. In vitro studies do not 
demonstrate a cytochrome P450 enzyme effect.
Safety and tolerability
In phase 2 and 3 placebo-controlled studies, the treatment 
discontinuation rate due to adverse events in patients dosed 
with 1 mg twice daily was 12% for varenicline compared with 
10% for placebo in studies of 3 months’ treatment. In this 
group, the discontinuation rates for the most common adverse 
events in varenicline-treated patients were: nausea (3% vs 
0.5% for placebo), headache (0.6% vs 0.9% for placebo), 
insomnia (1.2% vs 1.1% for placebo), and abnormal dreams 
(0.3% vs 0.2% for placebo).
All the studies described above showed that the most 
common adverse event associated with varenicline treatment 
is nausea. For patients treated to the maximum recommended 
dose of 1 mg twice daily following initial dosage titration, 
the incidence of nausea was 30% compared with 10% in 
patients taking a comparable placebo regimen. In patients 
taking varenicline 0.5 mg twice daily following initial titra-
tion, the incidence was 16% compared with 11% for placebo. 
Nausea was generally described as mild or moderate and 
often transient.
However, for some subjects, it was persistent throughout 
the treatment period (Chantix: Package insert). Table 3 shows 
comparison of different varenicline studies with nausea being 
the most frequent adverse effects.
In a recent meta-analysis (Wu et al 2006), the follow-
ing adverse effects were reported signiﬁ  cantly more often 
among the varenicline group compared with placebo group: 
nausea (4 trials, n = 2506, OR 3.17, 95% CI 2.35–4.29, 
p   0.0001), ﬂ  atulence (2 trials, n = 1323, OR 2.04, 95% CI 
1.16–3.57, p = 0.01) and, constipation (4 trials, n = 2506, OR 
2.57, 95% CI 1.21–5.45, p   0.0001). Other severe events 
Table 2 Long-term safety of varenicline
Reference Design Sample (N) Treatment Adverse events Abstinence rate at wk 52
Williams (2006) Double-blind,
phase-2, multicenter, 
placebo controlled
52-wk follow up
251
126
Varenicline 1 mg twice 
daily
Placebo
Nausea 40.2% 
Abnormal 
dreams 22.7% 
Insomnia 19.1%
Varenicline 36.7% 
Placebo 7.9%
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included atrial ﬁ  brillation (Gonzales et al 2006), pneumonia, 
and stroke (Oncken et al 2006). There is no apparent effect 
of varenicline on clinical laboratory assessments, vital signs 
(blood pressure and heart rate), QTc, or ECG morphology 
(Faessel et al 2006b).
Expert opinion and future trends
To date all studies demonstrate that varenicline is associated 
with higher smoking cessation rates than placebo and may 
produce better cessation rates than bupropion. Varenicline 
represents a third class of drug with a different mechanism 
of action than either NRT or bupropion. Its novel mecha-
nism offers another approach to assist patients with smok-
ing cessation. Different forms of NRT and bupropion still 
remains the ﬁ  rst-line of treatment for smoking cessation, 
primarily because of over-the-counter availability and also 
some safety concerns surrounding varenicline. Varenicline 
has FDA approval as monotherapy, with further studies 
needed evaluating combination therapy. In the future, Pﬁ  zer 
plans to conduct a study to determine the multiple-dose 
pharmacokinetics of varenicline in young subjects in order 
to determine the appropriate doses for efﬁ  cacy and safety 
evaluations in adolescent smokers aged 12 through 16. They 
plan to establish if there is an age group (or weight group) in 
whom varenicline is poorly tolerated that its utility as an aid 
to smoking cessation should not be evaluated. Also, there are 
plans to conduct a prospective epidemiologic cohort study 
in pregnant women who are smokers and who are exposed 
to varenicline at the time of conception or any time during 
pregnancy. This information will be used to assess the poten-
tial risk to the fetus and/or live born infants.
One of the primary symptoms of smoking cessation 
is depression and it is hypothesized that smokers may be 
increasing central dopamine levels by reducing mono-
amine oxidase inhibitor activity (Ascher et al 1995). By this 
mechanism bupropion may be helpful to maintain central 
levels of dopamine through the process of cessation, although 
its effectiveness has been identiﬁ  ed to be independent of 
symptoms of depression (Hurt et al 1997). The partial 
agonists at nicotinic acetylcholine receptor like varenicline 
could stimulate the release of sufﬁ  cient dopamine to reduce 
craving and withdrawal while simultaneously acting as a 
partial antagonist by blocking the binding and consequent 
reinforcing effects of nicotine (Gonzales et al 2006). Vareni-
cline has been a unique central acting agent that opens the 
door to future studies. One of the drawbacks of varenicline 
is that its efﬁ  cacy is not assessed in combination with other 
therapies.
Other treatments that are currently being studied are 
rimonabant, a cannabinoid receptor agonist that appears to 
partially mediate central nervous system effects of nicotine 
in rodents (Cohen et al 2002). Also, several nicotine vaccines 
are under investigation. These vaccines are believed to induce 
antibodies against the nicotine molecule preventing the drug 
from reaching neural receptors that produce the effects nor-
mally associated with smoking (Pentel et al 2000).
Systematic implementation of effective cessation inter-
ventions should be a major focus of public health, with 
greater emphasis placed on the dual role of the clinician and 
the health care delivery system. Finally, reducing the world-
wide tobacco burden will require complementary efforts to 
reduce initiation and promote cessation.
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